pharmaphorum

AUGUST 5, 2022

Over the past 15 years, more than 60% of asset growth among the top 30 biopharma companies came from acquisitions. Such inorganic growth is no longer viable, argues Pervaise Khan, Accenture’s UK Life Sciences Lead. And of course, all of this will feed into future treatments and positive patient outcomes – the sole purpose of pharma.

Biopharma 52

Biopharma Marketing Pharma Relationship management 52

Pharmaceutical Technology

MAY 15, 2023

Patent volumes related to pyridine derivatives Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies Bristol-Myers Squibb 146 Unlock company profile Corteva 135 Unlock company profile F. Its primary focus is on oncology, cardiovascular, immunology, and fibrotic therapeutic projects.

Pharmaceutical 52

Pharmaceutical Leads Pharmacology Medicine 52

pharmaphorum

JANUARY 24, 2023

A just-published report from the Medicines Manufacturing Industry Partnership (MMIP) – set up by the UK government and biopharma industry in 2014 to drive growth in the category – says the sector has the potential to be a driver for the UK economy in the next decade.

Manufacturing 104

Manufacturing Medicine Government Pharmaceutical manufacturing 104